Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment
The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexibl...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Healthcare |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9032/9/8/990 |
| _version_ | 1797523717189795840 |
|---|---|
| author | Herman Morchel David Clark Leighanne Buenvenida Chinwe Ogedegbe |
| author_facet | Herman Morchel David Clark Leighanne Buenvenida Chinwe Ogedegbe |
| author_sort | Herman Morchel |
| collection | DOAJ |
| description | The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexible strategies to continue to deliver efficient emergency care while maintaining appropriate physical distancing between suspect and non-suspect COVID-19 patients. The engagement of a unique rapidly deployable Mobile Satellite Emergency Department (MSED) with scalable capability from prompt care to resuscitation level allowed the emergency care team to optimize patient care and throughput. The MSED was strategically located adjacent to the ambulance entrance. While initially deployed to increase Emergency Department surge capacity, the MSED was repurposed to cohort and treat COVID patients with the monoclonal antibody, Bamlanivimab, who were expected to be discharged after treatment. This allowed for more efficient use of Emergency Department resources, including physical space and staffing. |
| first_indexed | 2024-03-10T08:46:58Z |
| format | Article |
| id | doaj.art-92ed78834d80495f82e91497a85678c5 |
| institution | Directory Open Access Journal |
| issn | 2227-9032 |
| language | English |
| last_indexed | 2024-03-10T08:46:58Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Healthcare |
| spelling | doaj.art-92ed78834d80495f82e91497a85678c52023-11-22T07:49:16ZengMDPI AGHealthcare2227-90322021-08-019899010.3390/healthcare9080990Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody TreatmentHerman Morchel0David Clark1Leighanne Buenvenida2Chinwe Ogedegbe3Hackensack University Medical Center, Hackensack Meridian School of Medicine—Hackensack Meridian Health, Hackensack, NJ 07601, USAJersey Shore University Medical Center—Hackensack Meridian Health, Neptune, NJ 07753, USAJersey Shore University Medical Center—Hackensack Meridian Health, Neptune, NJ 07753, USAHackensack University Medical Center, Hackensack Meridian School of Medicine—Hackensack Meridian Health, Hackensack, NJ 07601, USAThe COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexible strategies to continue to deliver efficient emergency care while maintaining appropriate physical distancing between suspect and non-suspect COVID-19 patients. The engagement of a unique rapidly deployable Mobile Satellite Emergency Department (MSED) with scalable capability from prompt care to resuscitation level allowed the emergency care team to optimize patient care and throughput. The MSED was strategically located adjacent to the ambulance entrance. While initially deployed to increase Emergency Department surge capacity, the MSED was repurposed to cohort and treat COVID patients with the monoclonal antibody, Bamlanivimab, who were expected to be discharged after treatment. This allowed for more efficient use of Emergency Department resources, including physical space and staffing.https://www.mdpi.com/2227-9032/9/8/990COVID-19Mobile Satellite Emergency DepartmentCOVID monoclonal antibody treatmentBamlanivimabCOVID-19 patient isolationCOVID-19 patient treatment area |
| spellingShingle | Herman Morchel David Clark Leighanne Buenvenida Chinwe Ogedegbe Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment Healthcare COVID-19 Mobile Satellite Emergency Department COVID monoclonal antibody treatment Bamlanivimab COVID-19 patient isolation COVID-19 patient treatment area |
| title | Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment |
| title_full | Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment |
| title_fullStr | Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment |
| title_full_unstemmed | Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment |
| title_short | Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment |
| title_sort | use of a unique mobile medical asset in covid monoclonal antibody treatment |
| topic | COVID-19 Mobile Satellite Emergency Department COVID monoclonal antibody treatment Bamlanivimab COVID-19 patient isolation COVID-19 patient treatment area |
| url | https://www.mdpi.com/2227-9032/9/8/990 |
| work_keys_str_mv | AT hermanmorchel useofauniquemobilemedicalassetincovidmonoclonalantibodytreatment AT davidclark useofauniquemobilemedicalassetincovidmonoclonalantibodytreatment AT leighannebuenvenida useofauniquemobilemedicalassetincovidmonoclonalantibodytreatment AT chinweogedegbe useofauniquemobilemedicalassetincovidmonoclonalantibodytreatment |